Ansa Biotechnologies Market Research Report
Company Overview
Company Name
Ansa Biotechnologies
Mission
To establish a new way to manufacture synthetic DNA that overcomes the limitations of traditional DNA synthesis methods, empowering scientists to develop solutions for the world’s biggest problems in health and sustainability.
Founding and Founders
Founded by scientists, specific founding details including the date and names of founders are not provided.
Key People
- Jason T. Gammack - Chief Executive Officer
- Dan Lin-Arlow - Chief Scientific Officer and co-founder
- Sebastian Palluk - Chief Technology Officer and co-founder
- Dr. Matthew F. McManus - Independent Director and Chairperson of the Board
Headquarters
No specific information on headquarters location is provided.
Number of Employees
No information is available.
Revenue
No information is available.
Notable Achievements
Ansa Biotechnologies is known for its innovative enzymatic DNA synthesis technology, enabling direct synthesis of complex DNA sequences up to 600 bp without requiring assembly.
Products
Ansa DNA Fragments
- Description: High-quality linear double-stranded DNA fragments.
- Key Features:
- No-assembly direct synthesis up to 600 bp.
- Accurate and reliable production.
- Useful for complex DNA sequences like promoters, UTRs, and CRISPR arrays.
Ansa Clonal DNA
- Description: Sequence-perfect clonal DNA.
- Key Features:
- Complete and contiguous DNA oligonucleotides up to 600 bp.
- No-assembly synthesis method.
- Suitable for applications requiring high accuracy and fidelity.
Recent Developments
Product Launches
- Ansa DNA Fragments and Ansa Clonal DNA: These products enable the synthesis of complex DNA sequences that are difficult or impossible to synthesize using legacy technologies. They are now commercially available and have been successfully utilized by customers in the company's early access program.
New Features and Technologies
- 600 bp Direct Synthesis Technology: This proprietary enzymatic technology can directly synthesize complex DNA sequences up to 600 bp without the need for assembly.
- World’s Longest Oligonucleotide: Achieved the synthesis of a 1005 base long oligonucleotide with industry-leading accuracy, providing a new frontier in oligonucleotide synthesis.
Partnerships
- Microsoft Research Collaboration: Ansa Biotechnologies partners with Microsoft Research to develop scalable and sustainable DNA data writing technology.
- TeselaGen Biotechnology Partnership: The partnership will enhance R&D workflows and enable early-stage DNA manufacturing.
Funding and Investment
- Series A Financing: Successfully closed an oversubscribed $68 million Series A financing to support the next-generation enzymatic DNA synthesis technology platform.
- Previous Funding Rounds: Raised $9.2 million in combined Seed and Pre-Seed financing rounds.
Strategic Appointments
- Jason T. Gammack as CEO: Jason T. Gammack joined as CEO, transitioning Dan Lin-Arlow to the Chief Scientific Officer role.
- Dr. Matthew F. McManus as Chair of the Board: Appointed as Independent Director and Chairperson of the Board, bringing extensive experience in life sciences.
Customer Success and Early Access Program
- Early Access Program Expansion: Ansa Biotechnologies expanded its early access program, offering more customers the benefits of their innovative DNA synthesis technology.
- First Shipments: Successfully delivered complex clonal DNA sequences to customers, including challenging promoter sequences with high GC and AT content.
Conclusion
Ansa Biotechnologies is at the forefront of innovative DNA synthesis, providing groundbreaking solutions that empower scientific research and biotechnological advancements. Through strategic partnerships, continuous technological innovation, and successful funding rounds, Ansa Biotechnologies continues to push the limits of DNA synthesis capabilities. For more updates and detailed information on products and services, visit their website or subscribe to their mailing list.
Disclaimer: This report is based on the publicly available data provided and may not capture all details of Ansa Biotechnologies' operations and achievements.
